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Background: In recent years, endovenous laser treatment (ELT) has been proposed to treat incompetent great saphenous
veins (GSV). This study reports the long-term outcome of ELT in a series of 500 patients.
Methods: Incompetent GSV segments in 500 patients (436 women, 64 men) with a mean age of 52.6 years (range, 19 to
83 years) were treated with intraluminal ELT using a 980-nm diode laser (Pharaon, Osyris, France). The GSV diameter
was measured by Duplex examination in an upright position in different GSV segments (1.5 cm below the saphenofemo-
ral junction, crural segment, condylar segment, and sural segment). These measurements were used to determine the
optimal linear endovenous energy density (LEED) for each segment. During treatment, patients were maintained in the
Trendelenburg position. Patients were evaluated clinically and by duplex scanning at 1 and 8 days, 1 and 6 months, and
at 1, 2, 3, and 4 years to assess treatment efficacy and adverse reactions.
Results: A total of 511 GSVs were treated. The mean diameter was 7.5 mm (range, 2.4 to 15.0). The LEED was tuned as
a function of the initial GSV diameter measured in the orthostatic position, from 50 J/cm (3 mm) up to 120 J/cm (15
mm). At the 1-week follow-up, 9.3% of the patients reported moderate pain. In the immediate postoperative period, the
closure rate was 98.0% and remained constant during the 4-year follow-up to reach 97.1%. After 1 year, a complete
disappearance of the GSV or minimal residual fibrous cord was noted. Major complications have not been detected; in
particular, no deep venous thrombosis. Ecchymoses were seen in 60%, transitory paresthesia was observed in 7%. There
was no dyschromia, superficial burns, thrombophlebitis, or palpable indurations. Complementary phlebectomy was done
in 98% of patients. Failures occurred only in large veins (saphenofemoral junction diameter>1.1 cm or for GSV truncular
diameter >0.8 cm)
Conclusion: ELT of the incompetent GSV with a 980-nm diode laser appears to be an extremely safe technique,
particularly when the energy applied is calculated as a function of the GSV diameter. It is associated with only minor
effects. Currently, ELT has become the method of choice for treating superficial veins and has almost replaced the
treatment of traditional ligation and stripping. (J Vasc Surg 2007;46:1242-7.)Lower-extremity venous insufficiency is a common
medical condition afflicting 25% of women and 15% of men
in the United States and in Europe. Great saphenous vein
(GSV) reflux is the most common underlying cause of
significant varicose veins. Traditional treatment of GSV
reflux has been surgical removal of the GSV1; however,
recurrence in 30% to 60% of cases is reported,2 and it is also
associated with significant perioperative morbidity.
Less-invasive surgical treatments, including high liga-
tion of the GSV at the saphenofemoral junction (SFJ), have
been attempted in the hope that gravitational reflux would
be controlled while the vein is preserved for possible use as
a bypass graft. Unfortunately, ligation of the GSV alone
usually results in recurrent varicose veins. Recurrence has
been the rule even when high ligation has been combined
with phlebectomy of varicose tributaries or retrograde scle-
rotherapy. Therefore, when it is determined that GSV
reflux is the principal underlying problem, treatment
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1242should involve eliminating this source of reflux with abla-
tion of any associated incompetent venous segments.3
Although inadequate surgery of the saphenofemoral
junction and progression of disease are mechanisms that
explain some cases of recurrence, another important mech-
anism is neovascularization of the junction area after ve-
nous surgery. Histologic evidence has clearly shown that
neovascularization is the principle cause of recurrence.4
Minimally invasive techniques have been developed
within the last few years as alternatives to surgery in an
attempt to reduce morbidity and improve recovery time.
Endovenous laser treatment (ELT) is one of the most
promising of these new techniques, and numerous studies
have since demonstrated that it is safe and efficacious.
Several wavelengths have been proposed, respectively
810, 940, 980, 1064, and 1320 nm,5-9 with 810, 940 and
980 nm the most commonly used. At these wavelengths,
power is usually set between 10 and 15 W. The energy is
administered endovenously, either in a pulsed fashion
(pulse duration, 1 to 3 seconds) with fiber pullback in 3- to
5-mm increments every 2 seconds or continuously with a
constant pullback of the laser fiber at a velocity of 1 to 3
mm/s. At these settings, the average linear endovenous
energy density (LEED) that is commonly used to report
the dose administered to the vein is 20 J/cm to 140
J/cm.10,11 These doses induce heating of the vein wall,
which is necessary to cause collagen contraction and de-
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ening, leading to luminal contraction, venous thrombosis,
and vein fibrosis.12
Tumescent anesthesia is always delivered, so patients
feel no pain during ELT ablation at the suggested or
commonly used laser settings. This tumescent anesthesia
has the two functions of compressing and reducing the
diameter of the veins as well as acting as a protective barrier,
minimizing the risk of heat-related damage to adjacent
tissues.13,14 The discomfort felt by patients occurs 5 to 8
days after the procedure and is related to the inflammation
resulting from successful endovenous ablation (ie, wall
thickening).15 It is not related to the presence or degree of
ecchymosis nor is it the result of nontarget laser damage to
perivenous tissue.
This study reports the effectiveness and safety of ELT of
the GSV from a large number of patients from S.E.L.
Angéio-Phlébo Interventionnelle, Lomme, France with
long-term follow-up results.
MATERIALS AND METHODS
Patient selection. Directed history and physical exam-
ination, including an evaluation by duplex ultrasound im-
aging of the superficial venous system, was performed on
limbs of subjects with GSV. Study inclusion criteria in-
cluded varicose veins caused by SFJ incompetence with
GSV reflux as demonstrated by duplex ultrasound imaging,
age at least 18 years, and ability to return for scheduled
follow-up examinations for 12, 24, 36, and 48months after
endovenous laser treatment. Exclusion criteria included
nonpalpable pedal pulses, cardiovascular disease, inability
to ambulate, deep venous thrombosis (DVT), general poor
health; pregnancy, nursing, or plans to become pregnant
during the course of participation in the investigation; and
extremely tortuous GSVs that would not allow endovenous
catheterization and passage of the laser fiber as identified on
pretreatment venous duplex US mapping.
After initial consultation and evaluation, subjects meet-
ing the appropriate criteria were offered surgery vs ELT.
Nearly all subjects chose ELT rather than surgical ligation
and stripping. The study protocol was approved by our
local ethics committee. All patients gave written informed
consent before treatment.
Protocol. This prospective cohort observational study
included 500 patients (436 women, 64 men) with a mean
age of 52.6 years (range, 19 to 83 years) who underwent
ELT of incompetent GSV segments with 980-nm diode
laser energy delivered intraluminally. To reduce the
amount of blood inside the vein, the patients were main-
tained in Trendelenburg position in which the patient is on
an elevated and inclined plane at 20° with the head down
and legs and feet over the edge of the table.16
Procedure. Duplex ultrasonography (Aloka 3500,
Decines, France) was performed in the upright position to
map incompetent sources of venous reflux and then to
mark the skin overlying the incompetent portion of the
GSV starting at the SFJ. GSV diameter was measured in
upright position in different locations (1.5 cm below theSFJ, crural segment, condylar segment and sural segment)
to select the appropriate LEED for each segment.
In an outpatient special procedure room in the hospital,
the patient was placed in the Trendelenburg position for
treatment of the GSV. The target extremity was sterilely
prepared and draped. Under ultrasound guidance through
a sterile ultrasound probe cover, the GSV was visualized at
the knee level. The saphenous vein was percutaneously
punctured with a 21-gauge needle under ultrasound guid-
ance. A 5F microintroducer guidewire was threaded
through the needle, followed by the introducer. A 0.035-
inch guidewire was passed under ultrasound guidance up to
the SFJ, and a 5F introducer was placed over the guidewire.
A 600-m optical fiber (Osyfibre: PH-980-15-600-3,
Osyris, Hellemmes, France) connected to a 980-nm diode
laser (Pharaon, Osyris, Hellemmes, France) was passed
through the introducer to the SFJ. Its position was verified
by ultrasound imaging and by visualization of the aiming
beam through the skin.
Duplex control was used to guide the injection of 7- to
8-mL aliquots of a solution containing 10 mL of lidocaine
(1%) with epinephrine, 10 mL of lidocaine (1%) without
epinephrine, and an additional 60 mL of physiologic se-
rum. The injections were performed into the fascial space
surrounding the vein at intervals down its length.
The laser fiber was delivered endovenously 1 to 2 cm
below the SFJ and along the course of the GSV. The laser
fiber and catheter were slowly withdrawn in 3-mm incre-
ments using a graduated scale. The parameter was 10 W in
continuous mode with bursts of laser energy. LEED was
tuned as a function of the GSV diameters measured in the
upright position for each segment: 1.5 cm below the SFJ,
crural segment, condylar segment, and leg segment. The
LEED applied was 50 J/cm for GSV diameters between 2
and 4.5 mm, 70 J/cm for 4.5 to 7 mm, 90 J/cm for 7 mm
to 10mm, and up to 120 J/cm for larger diameters. Con-
sequently, the pulse duration was adjusted for each individ-
ual GSV segment from 1.2 seconds (2 mm) up to 6 seconds
(10 mm). The last pulse was controlled by duplex ultra-
sound imaging to avoid any skin burn and delayed healing.
Concomitant ambulatory phlebectomy was done in 98% of
the patients in this series.
Venous compression was applied postoperatively for 24
hours by irremovable compression bandage. The patients
were also asked to wear full-thigh class 3 compression
stockings during the day for 3 weeks. Patients were in-
structed to walk immediately after the procedure and to
continue their normal daily activities with vigorous work-
outs. All patients received the nonsteroidal anti-inflamma-
tory drug piroxicam (Feldene, Pfizer, New York, NY) for 5
days.
Follow-up examinations. Patients were re-examined
at day 1 after the procedure, at 1 week, at 1 and 6 months,
and at 1, 2, 3, and 4 years. Patients received duplex scan-
ning and were re-evaluated functionally and clinically.
Treatment-related side effects and complications were re-
corded. Symptoms of interest were the presence of ecchy-
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The duration of all symptoms was recorded.
Statistical analysis. Univariate Kaplan-Meier life-
table analysis was used to calculate failure rate, and the 95%
confidence interval of the survival rate was also computed.
Statistical analysis was performed using SAS 9.1 software
(SAS Institute Inc, Cary, NC).
RESULTS
Of the 500 patients who underwent ELT of the GSV,
436 were women and 64 were men, and their median age
was 52.6 years (range, 19 to 83 years). A total of 511 limbs
were treated, and according to the CEAP classification of
venous disorders, 388 were C2EpAS2 (GSV above the
knee) and 123 were C2EpAS3 (GSV below the knee).
The mean GSV diameter, measured in the orthostatic
position, was 5.88  2.23 mm (range, 2.4 to 15.0 mm).
The mean length of GSV treated was 32.2  14.4 cm
(range, 15 to 86 cm). In the immediate postoperative
period, successful occlusion, defined as vein occlusion with
absence of flow, was noted in 501 GSVs (98%). This initial
success rate remained almost constant during the follow-up
period to reach 97.1% at 4 years (Table I, Fig). A total
disappearance of the GSV or minimal residual cord was
noted in 40% of patients at the 6-month follow-up, mainly
in younger patients. At 1 year, a complete disappearance of
the GSV or minimal residual fibrous cord was noted for all
patients.
The analysis of failures (Table II) shows that the first
group of patients with early failures (2- and 4-year follow-
up) may have been due to inadequate initial treatments;
however, most recurrences were seen at 6 months. In this
series, failures occurred only in large veins (SFJ diameter
1.1 cm in diameter for GSV truncular diameter 0.8 cm
in diameter). In three patients who had early failure, closure
was noted at the 1-month follow-up. For these three pa-
tients, SFJ diameter was 9 mm and GSV troncular diameter
was 6.5 mm.
Major complications have not been detected; in partic-
ular, noDVT. Ecchymoses were seen in 60%, with amedian
duration of 2 weeks. Transitory paresthesia was observed in
7% of treated legs, with a median duration of 2 weeks
(maximum duration, 4 weeks). At 1-week follow-up,
Table I. Clinical results during 4 years of follow-up
Follow-up period GSVs, No.
Successful
treatment, %
1 day 511 98
8 days 511 98
1 month 509 98.4
6 months 466 95.7
1 year 408 96.8
2 years 269 97.8
3 years 141 99.3
4 years 34 97.1
GSV, Great saphenous veins.moderate pain was reported in 9.3% of the patients, andthey received analgesics for 1 more week. No dyschromia,
superficial burns, thrombophlebitis, or palpable indura-
tions were observed.
The compliance rate for class 3 compression was 100%
at 1 week and 70% at 3 weeks. This rate was assessed using
a patient questionnaire at the 1-month follow-up.
DISCUSSION
Valvular incompetence of the GSV is themost common
contributor to primary varicose veins. ELT of the GSV has
been widely accepted, and numerous studies have been
published, Studies with 400 patients and with a 4-year
follow-up are very limited, however:
● In 2003, Min et al3 published results on 499 GSV in
423 subjects with varicose veins treated during a 3-year
period with an 810-nm diode laser. Successful occlu-
sion of the GSV, defined as absence of flow on color
Doppler imaging, was noted in 490 of 499 GSVs
(98.2%) after initial treatment, and 113 of 121 limbs
(93.4%) followed up for 2 years have remained closed,
with the treated portions of the GSVs not visible on
duplex imaging. Forty subjects have been followed up
for 3 years and no new recurrences were seen at 2 or 3
years that were not present at the 1-year follow-up.3
● In 2005, Duran presented a study including 517 GSV
in 426 patients with a 24-month follow-up. Among
112 GSV followed up at least 24 months, 98% re-
mained closed or reabsorbed.17
● In 2006, the Italian Endovenous-laser Working
Group18 reported a cooperative multicenter clinical
study in 1050 patients (1076 limbs) during a 6-year
period but with only a 3-year follow up for all the
centers using duplex scanning. Thus far, the total
occlusion rate has been 97%.
● In 2007, Sadick and Wasser19 reported their 4-year
Fig. Success rates. The numbers along the axis represent the
numbers of veins available for analysis at intervals through the
study. The dotted lines represent 95% confidence intervals. GSV,
Great saphenous vein.experience with ELT plus ambulatory phlebectomy for
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recurrence rate was, respectively 5.9%, 3.6%, 3.4%, and
0% at 1, 2, 3, and 4 years of follow-up. In this study,
however, only 90 patients (94 limbs) were treated, and
results are reported for only three patients at 4 years.19
Thus, the present study is one of the largest studies
performed in a single center with a 4-year follow-up.
The experience gained by our group through years has
shown that the energy applied during treatment was the
main determinant of success; hence, although not perfect,
LEED remains our choice when comparing energy. We
adapted LEED as a function of GSV diameter measured in
upright position. Because thermal damage of the inner vein
wall (tunica intima) is required to achieve the tissue alter-
ations necessary to lead the vein to permanent occlusion,
mathematic modeling of ELT has confirmed that LEED
should be chosen as a function of the GSV diameter.20,21
In contrast to the mode of action of radiofrequency
ablation as used in the VNUS closure system (VNUS
Medical Technologies, Inc, San Jose, Calif), where a signif-
icant shrinkage of the vessel wall is observed, Proebstle et
al22 has clearly demonstrated that when performing ELT,
permanent occlusion, reported at 3 months, can only be
obtained by thermal damage of the tunica intima inner vein
wall. This observation was confirmed by the histologic
study performed by Corcos et al23 after ELT with an
810-nm diode laser. They showed that when permanent
occlusion was observed, the endothelium and intima were
always damaged. The adventitia and the externa appeared
Table II. Patients with immediate and late failures
Patient 1 day 8 days 1 month 6 months 1 year
1 Yes Yes Yes Yes Yes
2 Yes Yes Yes Yes Yes
3 Yes Yes Yes Yes Yes
4 Yes Yes Yes Yes Yes
5 Yes Yes Yes Yes Yes
6 No No No Yes Yes
7 Yes Yes No No No
8 No No No Yes Yes
9 No No No Yes Yes
10 No No No Yes Yes
11 No No No Yes Yes
12 No No No Yes Yes
13 No No No Yes Yes
14 No No No Yes Yes
15 Yes Yes Yes Yes . . .
16 No No No Yes . . .
17 No No No Yes . . .
18 Yes Yes Yes Yes . . .
19 No Yes Yes Yes . . .
20 No No No Yes . . .
21 No No No Yes . . .
22 Yes Yes No . . . . . .
23 Yes No No . . . . . .
Total 10 10 8 20 13
GSV, Great saphenous vein; SFJ, saphenofemoral junction.to be involved in only a few of the specimens. They con-cluded that that success was independent of the vessel wall
thickness.23
The role of blood during the ELT must be considered.
Because the presence of blood could reduce the light
transmitted to the vein wall, it is usually recommended to
reduce the amount of blood by emptying the vein lumen
using leg elevation by Trendelenburg positioning, perisa-
phenous subcutaneous tumescent saline solution infiltra-
tion, and manual compression. If the laser light energy is
entirely absorbed by the blood, the initial success rate is
mainly due to a thrombotic effect, but the thrombus disso-
lution leads to a recanalization.11
The proper tumescent anesthetic technique is essential
for this procedure to be safe and painless. With ultrasound
guidance, only 300 to 400 mL of fluid is required. The
procedure is painless, and a surrounding fascial envelope of
the tumescent solution provides a margin of safety so heat
damage to surrounding structures does not occur.24
The principal finding in this study is that ELT with a
980-nm diode laser system, when performed under tumes-
cent local anesthesia, is a clinically feasible and well-toler-
ated technique. Because vein access is with a 21-gauge
needle, it is truly minimal procedure that leaves a nearly
invisible scar on the patient’s skin.
The efficacy of ELT in obtaining early occlusion of the
GSV is very satisfactory, with a 98.4% closure rate at the
1-month follow-up. These results are very similar to those
reported by other teams. A 97% closure rate was obtained
by Proebsle et al5 with a similar follow-up. Min et al3
years 3 years 4 years
SFJ diameter,
mm
GSV troncular
diameter, mm
Yes Yes Yes 13.0 8.0
Yes . . . . . . 13.0 8.0
Yes . . . . . . 12.0 8.0
Yes . . . . . . 12.0 7.5
Yes . . . . . . 12.0 8.0
Yes . . . . . . 9.5 7.5
. . . . . . . . . 8.5 6.08
. . . . . . . . . 12.0 8.0
. . . . . . . . . 11.0 8.0
. . . . . . . . . 10.0 7.0
. . . . . . . . . 9.0 6.0
. . . . . . . . . 10.0 8.5
. . . . . . . . . 13.0 8.0
. . . . . . . . . 11.0 8.0
. . . . . . . . . 15.0 8.0
. . . . . . . . . 11.0 7.0
. . . . . . . . . 13.0 8.0
. . . . . . . . . 15.0 8.5
. . . . . . . . . 12.5 7.0
. . . . . . . . . 11.5 8.0
. . . . . . . . . 13.0 8.0
. . . . . . . . . 8.5 6.5
. . . . . . . . . 9.5 6.5
6 1 12reported a 97% closure rate 1 week after initial treatment.
JOURNAL OF VASCULAR SURGERY
December 20071246 Desmyttère et alAt 2-year follow-up, the closure rate was 97.8% in our
series and 93.4% in the Min et al series. Repeated treat-
ments were sometimes performed, however, which is not
the case in our study, where patients were only treated
once. Sadick et al19 obtained a closure rate of 96.4%.
Duran17 obtained a 24-month follow-up on 112 GSV (611
initially), among which 98% have remained closed. Dissel-
hoff et al25 reported that the treated GSV was not identifi-
able with duplex ultrasound in 89% and 90% of limbs at the
1- and 2-year follow-up, respectively. A complete disap-
pearance of the GSV or minimal residual fibrous cord was
noted in our study.
At 3-year follow-up, the total occlusion rate of GSVwas
99.3%. This is similar to the 96.7% rate reported by Agus et
al18 and the 96.6% rate of Sadick et al19 after 36 months. At
4 years, the closure rate was 97.1 %. Sadick et al have
obtained 100% occlusion, but with a follow-up on three
patients only.19
In our series, recanalizations were only observed when
SFJ diameter was 1.1 cm or for GSV troncular diameters
0.8 cm. This observation is in agreement with math-
ematic modeling demonstrating that higher energy should
be necessary to treat a larger GSV diameter. Several authors
have proposed to use higher LEED to improve the closure
rate. Proebstle et al11 observed that nonocclusion and early
reopening of the GSV is energy-dependent.
Timperman et al26 compared patients treated with an
average energy delivered of 63.4 J/cm (range, 20.5 to
137.8 J/cm) and a second group treated with 46.6 J/cm
(range, 25.7 to 78 J/cm). They showed that failures were
mostly associated with the lower LEED. However, treat-
ment failures were also identified in patients who received
doses of80 J/cm ormore. Energy delivery for the failures
was 120, 80, 110, 98, and 80 J/cm (mean J/cm [SD], 98
[18]), respectively.26
That failures were always observed when SFJ diameter
was 1.1 cm or for GSV troncular diameter 0.8 cm,
where the content of blood is very important even in the
Trendelenburg position, confirms that laser irradiation was
not sufficient to heat the vessel wall. One can hypothesize
that blood remaining inside the lumen could absorb the
laser light energy, limiting consequently the light transmit-
ted to the vessel wall.
Side effects are also energy-dependent. Superficial
burns and palpable indurations are sometimes associated
with LEED 100 J/cm. In our study, LEED was chosen
to obtain maximum efficiency but also to limit the treat-
ment-related side effects and complications. No dyschro-
mia, superficial burns, thrombophlebitis, or palpable indu-
rations were reported in our study. These results confirm
that our decision to adapt the LEED to the GSV diameter
has led to a high rate of GSV closure while minimizing the
side effects. The ecchymosis rate in our study was 60%,
which is similar to the 61.7% rate reported by Sadick et al.19
It also compares favorably with the ecchymosis rates ob-
served by Proebstle et al27 of 73.2% (940 nm, 15W, 1
second, pulsed), 78.2% (940 nm, 15W, continuous wave)
and 81.2 % (940 nm, 20W, continuous wave).Most clinical studies published on ELT have not con-
sidered postprocedural pain. The difficulty with studies that
evaluate pain is the significant variation in pain tolerance
among patients. What may seem like “being sore” to one
patient might be considered severe pain to another. Even
objective measures such as carefully recording usage of pain
medication can vary because patients have different pain
tolerances. For example, Gibson et al28 reported pain in
97% of treated patients, and in the series reported by
Proebstle et al,27 72% of patients complained of pain. In
their series, pain was treated with analgesics twice daily, and
the median duration of pain and the demand for analgesics
lasted usually 1 week (maximum duration, 2 weeks). In our
series, analgesics were systematically given to the patients
for 5 days, and at the 1-week follow-up, only 9.3% reported
moderate pain.
Transitory paresthesia was observed in 7% of treated
legs, with a median duration of 2 weeks. Huang et al29
noted paresthesia in 7.2 % of patients. In another study,
Proebstle et al30 reported an 11% incidence of paresthesia
for 3 to 8 weeks after treatment, despite all patients being
treated with low-molecular weight heparin and postopera-
tive graduated compression for 8 days.
CONCLUSION
ELT of the incompetent GSV with a 980-nm diode
laser appears to be an extremely safe technique, particularly
when the energy applied is calculated as a function of the
GSV diameter. It is associated with only minor effects.
Currently, ELT has become the method of choice for
treating superficial veins and has almost replaced the tradi-
tional treatment of ligation and stripping.31,32
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